Cells to Society: Uncommon insights to understanding, treating and preventing common cancers
Living At Your Peak
Dr. Eric R. Fearon, M.D., Ph.D.
Dr. Arul M. Chinnaiyan, M.D., Ph.D.
Dr. Kathleen R. Cho, M.D.
Dr. Nithya Ramnath, M.D.
Dr. Sofia Diana Merajver, M.D.
Saturday, August 19, 2017
2 p.m. to 5:30 p.m.
The event will be held in Vail. Specific location will be announced soon.
CANCER. It’s the disease Americans fear most, the disease we most want to cure. It can be devastating for a patient, a family, or a community, instantly reminding us how precious life is and inspiring us to rally around a common goal.
Research advances over the past three decades have yielded great successes in improving patient survival and in achieving cures for common cancers such as breast cancer, ovarian cancer, lung cancer, esophageal cancer and prostate cancer.
With the rare opportunity to host five specialists from the University of Michigan Comprehensive Cancer Center (UMCCC), the Vail Symposium will present a two-part panel program where everyone–medical doctors and patients to those simply interested in learning about measures of treatment and prevention of common cancers–can grasp exciting new breakthroughs in cancer research.
Part 1 – 2 pm – 3:30 pm
30-minute break with refreshments and an opportunity for the audience to interact with the panelist
Part 2 – 4 pm to 5:30 pm
There will be a 30-minute reception following part 2 where the audience will have the opportunity to interact with the panelists.
MEET THE PANEL
Dr. Eric Fearon was named Director at the UMCCC in September of 2016. He is a Professor of Oncology and also a Professor in the Departments of Internal Medicine, Human Genetics, and Pathology at the University of Michigan Medical School. Dr. Fearon has authored more than 135 peer-reviewed research manuscripts and more than 60 review/editorial articles and book chapters. He has pursued research in the cancer genetics field, particularly investigations of selected gene defects that underlie colon and rectal tumor development and progression to advanced stages. He is currently an editorial board member or editor at 10 journals, including The Journal of Biological Chemistry, Current Biology, Journal of Clinical Investigation, and Gastroenterology.
Arul M. Chinnaiyan, is a Howard Hughes Medical Institute Investigator, American Cancer Society Research Professor, and S.P. Hicks Endowed Professor of Pathology and Urology at the University of Michigan. He has co-authored over 400 manuscripts and has been designated an A. Alfred Taubman Medical Research Institute Scholar. Dr. Chinnaiyan’s research has focused on functional genomic and bioinformatics approaches to study cancer for the purposes of understanding cancer biology as well as to discover clinical biomarkers.
Specialty: Prostate Cancer
Dr. Kathleen R. Cho is the head of the gynecologic pathology section of Surgical Pathology at the University of Michigan Health System. Dr. Cho has established a research laboratory that uses a range of systems and approaches to study the molecular pathogenesis of ovarian cancers. These include technologies to generate comprehensive molecular profiles of primary human carcinomas and their precursors, in vitro systems to study altered signaling pathways and effects of specific molecular alterations in cancer cells, and genetically engineered mouse models of cancer.
Specialty: Ovarian Cancer
Dr. Nithya Ramnath is an Associate Professor of Medicine at the UMCCC. She is a thoracic oncologist and her research portfolio spans several aspects of lung cancer and has been published by more than 80 peer-reviewed publications. Her laboratory research is centered on deregulation of Vitamin D metabolism in lung cancer. . Currently, she is studying how CYP24A1 (rate limiting enzyme in Vitamin D catabolism) is involved in the cell cycle in lung cancer. More recently, she has been working to identify specific T cell receptor markers that might predict durable response to immunotherapy.
Specialty: Lung Cancer
Dr. Sofia Diana Merajver, an expert in breast cancer genetics, is the medical director of the Breast and Ovarian Cancer Risk Evaluation Program at the U-M Cancer Center. Dr. Sofia Merajver received a doctoral degree in physics from the University of Maryland and a medical degree from the University of Michigan. She completed a residency in internal medicine and a fellowship in oncology at the University of Michigan before joining the faculty in 1994. Her research interests include the molecular genetics of breast cancer, gene function and cancer risk assessment.
Specialty: Breast Cancer
CONNECT WITH UMCCC
Let the Antlers at Vail take care of you.
The Antlers at Vail has been the signature hotel partner of the Vail Symposium since 2003, housing hundreds of prominent speakers from around the world. From U.S. Senators and Congressman to renowned entertainers and authors, the Antlers has taken the best care of anyone associated with the Vail Symposium. Located steps from the Lionshead Gondola and Vail’s best bars and restaurants, let the Antlers take care of you.